Theravance Biopharma (TBPH) FCF Margin Growth (1y) (2014 - 2026)
Powered by 
Analysis
Theravance Biopharma (TBPH) FCF Margin Growth (1y) (2014 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -89.00 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -1,183.00 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 26,102.00 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 869.00 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 769.00 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 811.00 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 19,111.00 |
| 10 | Theravance Biopharma | 882.99 Mn | 495.33 Mn | - | -82,792.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -82,792.00 |
| Mar 31, 2026 | 13,434.00 |
| Dec 31, 2025 | -741.00 |
| Sep 30, 2025 | -166.00 |
| Jun 30, 2025 | 82,555.00 |
| Mar 31, 2025 | 28,737.00 |
| Dec 31, 2024 | 289.00 |
| Sep 30, 2024 | -1,492.00 |
| Jun 30, 2024 | 6,543.00 |
| Mar 31, 2024 | 10,905.00 |
| Dec 31, 2023 | 83,995.00 |
| Sep 30, 2023 | 16,136.00 |
| Jun 30, 2023 | 3,211.00 |
| Mar 31, 2023 | 8,738.00 |
| Dec 31, 2022 | -54,294.00 |
| Sep 30, 2022 | 36,523.00 |
| Jun 30, 2022 | 26,050.00 |
| Mar 31, 2022 | 29,833.00 |
| Dec 31, 2021 | 11,346.00 |
| Sep 30, 2021 | -10,941.00 |